6 results on '"Valteau-Couanet, D."'
Search Results
2. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations
- Author
-
Boland, I, primary, Vassal, G, additional, Morizet, J, additional, Terrier-Lacombe, M-J, additional, Valteau-Couanet, D, additional, Kalifa, C, additional, Hartmann, O, additional, and Gouyette, A, additional
- Published
- 1999
- Full Text
- View/download PDF
3. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
- Author
-
Schleiermacher, G., Michon, J., Huon, I., d'Enghien, C. Dubois, Klijanienko, J., Brisse, H., Ribeiro, A., Mosseri, V., Rubie, H., Munzer, C., Thomas, C., Valteau-Couanet, D., Auvrignon, A., Plantaz, D., Delattre, O., Couturier, J., and Société Française des Cancers de l'Enfant (SFCE)
- Subjects
NEUROBLASTOMA ,TUMORS in children ,GENE expression ,CHROMOSOME abnormalities ,COMPARATIVE genomic hybridization ,PROGNOSIS - Abstract
Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases, whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were present in eight cases. A type 1 profile was observed more frequently in localised disease (P<0.0001), and in patients of less than 12 months at diagnosis (P<0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-rank test; P<0.0001), but also in the subgroup of patients with localised disease (log-rank test, P=0.007). In multivariate analysis, the genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
4. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.
- Author
-
Rubie, H., Coze, C., Plantaz, D., Munzer, C., Defachelles, A.S., Bergeron, C., Thomas, C., Chastagner, P., Valteau-Couanet, D., Michon, J., Mosseri, V., Hartmann, O., and Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique
- Subjects
NEUROBLASTOMA ,DRUG therapy ,INFANT disease treatment ,THERAPEUTICS ,THERAPEUTIC use of antineoplastic agents ,SURVIVAL ,RESEARCH ,ONCOGENES ,RESEARCH methodology ,CANCER relapse ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,CYCLOPHOSPHAMIDE ,VINCRISTINE - Abstract
The purpose of this study was to evaluate the efficacy of low-dose chemotherapy in infants with localised and unresectable neuroblastoma (NB). All consecutive infants with localised NB and no N-myc amplification were eligible in the SFOP-NBL 94 study. Primary tumour was deemed as unresectable according to imaging data showing any risk of immediate resection. Diagnostic procedures and staging were conducted according to INSS recommendations. For children, provided that they had no threatening symptom (i.e. vital risk or dumb-bell NB with neurologic deficit), chemotherapy consisted in low-dose cyclophosphamide (5 mg(-1)kg day(-1) x 5 days) and vincristine (0.05 mg kg(-1) at day 1)-CV and repeated one to three times every 2 weeks until surgical excision can be safely performed. No postoperative treatment was given. Between January 1995 and December 1999, 134 consecutive infants with localised NB were registered in the study, of whom 39 had an unresectable NB without N-myc amplification. Among them 28 had no threatening symptom and received CV according to the protocol. Objective response was observed in 14 (50%) and the other 14 were given second-line chemotherapy because of no response. Surgery was attempted in 38 patients including 14 after CV alone, leading to complete resection in 23. Relapses occurred in four patients all local. Survival and event-free survival were 100 and 90+/-5% with a median follow-up of 55 months (range 33-93). In conclusion primary low-dose chemotherapy without anthracyclines is efficient in about half of the infants presenting with an unresectable NB and no N-myc amplification, allowing excellent survival rates without jeopardising their long-term outcome even for nonresponding patients who received standard regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
5. Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?
- Author
-
Bougas N, Allodji RS, Fayech C, Haddy N, Mansouri I, Journy N, Demoor C, Allard J, Thebault E, Surun A, Pacquement H, Pluchart C, Bondiau PY, Berchery D, Laprie A, Boussac M, Jackson A, Souchard V, Vu-Bezin G, Dufour C, Valteau-Couanet D, de Vathaire F, Fresneau B, and Dumas A
- Subjects
- Male, Humans, Child, Survivors, Neoplasms epidemiology, Cancer Survivors, Cardiomyopathies epidemiology, Cardiomyopathies etiology, Cardiomyopathies diagnosis, Neuroblastoma
- Abstract
Background: We aimed to study adherence to cardiac screening in long-term childhood cancer survivors (CCS) at high risk of cardiomyopathy., Methods: This study involved 976 5-year CCS at high risk for cardiomyopathy from the French Childhood Cancer Survivor Study. Determinants of adherence to recommended surveillance were studied using multivariable logistic regression models. Association of attendance to a long-term follow-up (LTFU) visit with completion of an echocardiogram was estimated using a Cox regression model., Results: Among participants, 32% had an echocardiogram within the 5 previous years. Males (adjusted RR [aRR] 0.71, 95% CI 0.58-0.86), survivors aged 36-49 (aRR 0.79, 95% CI 0.64-0.98), Neuroblastoma (aRR 0.53, 95% CI 0.30-0.91) and CNS tumour survivors (aRR 0.43, 95% CI 0.21-0.89) were less likely to adhere to recommended surveillance. Attendance to an LTFU visit was associated with completion of an echocardiogram in patients who were not previously adherent to recommendations (HR 8.20, 95% CI 5.64-11.93)., Conclusions: The majority of long-term survivors at high risk of cardiomyopathy did not adhere to the recommended surveillance. Attendance to an LTFU visit greatly enhanced the completion of echocardiograms, but further interventions need to be developed to reach more survivors., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
6. Educational and occupational outcomes of childhood cancer survivors 30 years after diagnosis: a French cohort study.
- Author
-
Dumas A, Berger C, Auquier P, Michel G, Fresneau B, Allodji RS, Haddy N, Rubino C, Vassal G, Valteau-Couanet D, Thouvenin-Doulet S, Casagranda L, Pacquement H, El-Fayech C, Oberlin O, Guibout C, and de Vathaire F
- Subjects
- Adolescent, Child, Child, Preschool, Cohort Studies, Female, France, Humans, Infant, Infant, Newborn, Male, Outcome Assessment, Health Care, Surveys and Questionnaires, Survivors, Health Occupations trends, Neoplasms epidemiology
- Abstract
Background: Although survival from childhood cancer has increased, little is known on the long-term impact of treatment late effects on occupational attainment or work ability., Methods: A total of 3512 five-year survivors treated before the age of 19 years in 10 French cancer centres between 1948 and 2000 were identified. Educational level, employment status and occupational class of survivors were assessed by a self-reported questionnaire. These outcome measures were compared with sex-age rates recorded in the French population, using indirect standardisation. Paternal occupational class was also considered to control for the role of survivors' socioeconomic background on their achievement. Multivariable analyses were conducted to explore clinical characteristics associated with the outcomes., Results: A total of 2406 survivors responded to the questionnaire and survivors aged below 25 years were included in the current analysis. Compared with national statistics adjusted on age and sex, male survivors were more likely to be college graduates (39.2% vs 30.9% expected; P<0.001). This higher achievement was not observed either for leukaemia or central nervous system (CNS) tumour survivors. Health-related unemployment was higher for survivors of CNS tumour (28.1% vs 4.3%; P<0.001) but not for survivors of other diagnoses. Survivors of non-CNS childhood cancer had a similar or a higher occupational class than expected., Conclusions: Survivors treated for CNS tumour or leukaemia, especially when treatment included cranial irradiation, might need support throughout their lifespan.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.